1239441-36-1 Usage
Description
6-Bromo-3-chloro-imidazo[1,2-a]pyrazine is a heterocyclic organic compound characterized by a fused imidazole-pyrazine ring system. It is a derivative of imidazo[1,2-a]pyrazine, featuring both bromine and chlorine as substituents on the heterocyclic ring. 6-Bromo-3-chloro-imidazo[1,2-a]pyrazine is known for its potential applications in medicinal chemistry and agrochemical industries due to its biological activity and reactivity.
Uses
Used in Medicinal Chemistry:
6-Bromo-3-chloro-imidazo[1,2-a]pyrazine is used as a building block in the synthesis of various pharmaceuticals. Its unique structural features and reactivity make it a valuable intermediate for the development of complex organic molecules with potential therapeutic applications.
Used in Agrochemical Industries:
In the agrochemical sector, 6-Bromo-3-chloro-imidazo[1,2-a]pyrazine serves as a key component in the creation of agrochemicals. Its biological activity contributes to the effectiveness of these products, which can be utilized in pest control and crop protection.
Used in Coordination Chemistry:
6-Bromo-3-chloro-imidazo[1,2-a]pyrazine also has potential as a ligand in coordination chemistry. It can be employed in the design and synthesis of new metal complexes, which may have various applications in different fields, including catalysis and material science.
Check Digit Verification of cas no
The CAS Registry Mumber 1239441-36-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,9,4,4 and 1 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1239441-36:
(9*1)+(8*2)+(7*3)+(6*9)+(5*4)+(4*4)+(3*1)+(2*3)+(1*6)=151
151 % 10 = 1
So 1239441-36-1 is a valid CAS Registry Number.
1239441-36-1Relevant articles and documents
SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF
-
Paragraph 0580-0581, (2020/02/19)
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases.
